(STEP A) SCREEN – LFT/ANTIGEN TEST FOR T14 IN NASAL SECRETIONS

(STEP B) CLINICAL DIAGNOSTIC TEST – IMMUNODETECTION TECHNOLOGY IN SALIVA

NBP-14 is the lead compound in the preclinical phase toward IND status and subsequent clinical testing in the near future. Neuro-Bio is also developing a pipeline that involves screening smaller, potentially more druggable variants.

Neuro-Bio is developing an authentic animal model of Alzheimer’s disease triggering AD-like symptoms after administration of the 14mer peptide in the brain. This work is being developed in partnership with the University of Oxford

Based on the findings that the 14mer peptide is involved in aberrant developmental conditions, Neuro-Bio is developing additional assets outside the neurodegenerative disease space, such as:

• ONCOLOGY: Neuro-Bio is exploring the anti-tumoral action of NBP14 in human colorectal cancer in collaboration with external partners
• DERMATOLOGY: Neuro-Bio is developing several applications of the T14-NBP14 technology for skin aging and skin disorders with external partners
• RAPAMYCIN SENSITIVE APPLICATIONS: Neuro-Bio is developing the use of NBP-14 as an alternative to rapamycin and avoiding its side effects due to its selectivity to mTOR1 (Ranglani et al. 2023)
• DIABETHIC RETINOPATHY: Neuro-Bio is developing the use of NBP-14 and derivatives as a ocular treatment for diabetic retinopathy